About Vaxxinity
Vaxxinity is a publicly listed company based in Dallas (United States) founded in 2019. Vaccines for neurological disorders and infectious diseases are developed. Vaxxinity has raised $26.96 million across 1 funding round. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is VAXXINITY, INC. Its competitors include Brii Biosciences, Affinivax and Pardes Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Vaxxinity was established in 2019 in Dallas, United States, within the biotechnology sector. Focus is placed on developing vaccines addressing neurological disorders and infectious diseases through proprietary synthetic peptide immunogens. These immunogens activate B- and T-cell responses while combining multiple antigens into multitope formulations. Key candidates include UB-612 for COVID-19, UB-311 and Tau for Alzheimers disease, UB-312 for Parkinsons disease, UB-313 for chronic migraine, and PCSK9 for hypercholesterolemia.
- Headquarters Dallas, United States
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website vaxxinity.com
- Social LinkedIn X Facebook
- Legal Name Vaxxinity, Inc.
- Net Profit-$56.93 M (USD)24.31as on Dec 31, 2023
- EBITDA-$56.05 M (USD)24.56as on Dec 31, 2023
- Total Equity Funding$26.96M (USD)
in 1 rounds
- Latest Funding Round$26.96M (USD), Series B
Mar 2021
Funding Insights of Vaxxinity
Vaxxinity has successfully raised a total of $26.96M through 1 strategic funding round. The most recent funding activity was a Series B round of $26.96 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $26.96M
- Total Rounds 1
- Last Round Series B — $26.96M
- First Round $26.96M
(Mar 2021)
All 1 funding rounds of Vaxxinity with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2021 | $26.96M | Series B | – | – | – |
People of Vaxxinity
30 people are tracked at Vaxxinity (6 in leadership, 22 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
Mark Joinnides | Chief of Staff | Leadership |
Jon Harrison | Chief Government Officer | Leadership |
Mei Mei Hu | CEO | Leadership |
Amy Fix | Chief Regulatory Officer | Leadership |
Lewis Yim | Director, Technology & Infrastructure | Leadership |
Michael Hellerstein | Head Of Operations | Leadership |
Kausik K. Ray | Advisor | Board & advisors |
Dirk Von Lewinski | Advisor | Board & advisors |
Stephen Nicholls | Advisor | Board & advisors |
Stephen D. Silberstein | Advisor | Board & advisors |
Frederick Raal | Advisor | Board & advisors |
Parviz Ghahramani | Advisor | Board & advisors |
Thomas Fleming | Advisor | Board & advisors |
Lou Reese | Co-Founder & Chairman | Board & advisors |
Brad Boeve | Advisor | Board & advisors |
Wayne Koff | Advisor | Board & advisors |
Nick Fox | Advisor | Board & advisors |
Peter H. Diamandis | Director | Board & advisors |
Peter Powchik | Director | Board & advisors |
Stanley A. Plotkin | Advisor | Board & advisors |
10 more people are available in the full profile.
Complete people profiles for Vaxxinity
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Vaxxinity
Vaxxinity is a publicly listed company on the OTC with ticker symbol VAXX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Nov 2021
- Listed onNASDAQ: VAXX
- Listed entityVaxxinity, Inc.
- Exchange sectorHealth technology
- ISINUS92244V1044
- Share price$0.03 (+34400% on the day) · 2026-10-13
- Market capitalisation$4.9M
- Volume (last session)102
Financials of Vaxxinity
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2023 | -$56.9M | -$56.0M | |
| 2022 | -$75.2M | -$74.3M | |
| 2021 | $66,000 | -$137.2M | -$124.0M |
Detailed financial statements for Vaxxinity
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Vaxxinity
3 dated milestones of Vaxxinity across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Vaxxinity is founded.
- Funding First funding round of $27.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Vaxxinity
Vaxxinity has 3 listed competitors in our database, 3 of them funded. They include Brii Biosciences, Affinivax and Pardes Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| briibio.com | 2018 | San Francisco, United States | $415M | 68 | Developer of biologics to treat hepatitis B infection | |
| affinivax.com | 2013 | Cambridge, United States | $359.49M | 132 | Technology-based conjugate vaccines against infectious diseases are developed. | |
| pardesbio.com | 2020 | Berkeley, United States | $51.61M | 29 | Therapeutics for pandemic diseases including SARS-CoV-2 are developed. |
Detailed competitors of Vaxxinity
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Vaxxinity
The website of Vaxxinity (vaxxinity.com) receives about 1.9K visits a month and ranks #8,488,244 among all websites worldwide, #7,388 in Biotechnology and Pharmaceuticals.
- Monthly visits1.9K
▼ 1.3% vs previous month
- Global rank#8,488,244
among all websites
- Category rank#7,388
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit1.6
- Average visit32 sec
- DevicesDesktop 21% · Mobile 79%
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Vaxxinity (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vaxxinity
Complete news archive for Vaxxinity
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vaxxinity
Vaxxinity was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Vaxxinity is headquartered in Dallas, United States. It is registered at Dallas, Texas, United States.
Vaxxinity is a funded company, having raised a total of $26.96M across 1 funding round to date. The company's 1st funding round was a Series B of $26.96M, raised on Mar 2021.
Vaxxinity was established in 2019 in Dallas, United States, within the biotechnology sector. Focus is placed on developing vaccines addressing neurological disorders and infectious diseases through proprietary synthetic peptide immunogens. These immunogens activate B- and T-cell responses while combining multiple antigens into multitope formulations. Key candidates include UB-612 for COVID-19, UB-311 and Tau for Alzheimers disease, UB-312 for Parkinsons disease, UB-313 for chronic migraine, and PCSK9 for hypercholesterolemia.
Vaxxinity's top competitors include Brii Biosciences, Affinivax and Pardes Biosciences.
Yes, Vaxxinity is publicly traded on OTC under the ticker symbol VAXX.
Vaxxinity operates through Vaxxinity, Inc..